1-11 of 11
Robert C. Doebele
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

Open Access
Nan Chen, Logan C. Tyler, Anh T. Le, Eric A. Welsh, Bin Fang, Andrew Elliott, Kurtis D. Davies, Thomas Danhorn, Gregory J. Riely, Marc Ladanyi, Eric B. Haura, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 92–105.
https://doi.org/10.1158/1535-7163.MCT-23-0218
Published: 03 January 2024
View articletitled, MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Open the PDF for MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2)

Free
Ecaterina E. Dumbrava, Christopher T. Chen, Gregory M. Cote, Glenn J. Hanna, Thomas E. Stinchcombe, Bradley Sumrall, Trisha Wise-Draper, Mohammed Kanaan, Steven Duffy, Christopher Sumey, Patrick Cobb, Naisargee Shah, Bo Zhang, Nora Ku, Robert C. Doebele, Mrinal Gounder
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B034.
https://doi.org/10.1158/1535-7163.TARG-23-B034
Published: 01 December 2023
View articletitled, Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2)
Journal Articles

Abstract P076: Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC

Free
Logan C. Tyler, Anh T. Le, Hala Nijmeh, Liming Bao, Kristen Turner, Jason Christianson, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P076.
https://doi.org/10.1158/1535-7163.TARG-21-P076
Published: 01 December 2021
View articletitled, Abstract P076: Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC
Journal Articles

Abstract P071: Phosphoproteomics identifies Mig6 as a key mediator of adaptive resistance to ALK/ROS1 oncogene inhibition

Free
Nan Chen, Anh T. Le, Eric A. Welsh, Bin Fang, Eric B. Haura, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P071.
https://doi.org/10.1158/1535-7163.TARG-21-P071
Published: 01 December 2021
View articletitled, Abstract P071: Phosphoproteomics identifies Mig6 as a key mediator of adaptive resistance to ALK/ROS1 oncogene inhibition
Journal Articles

Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

Free
Vijaya G. Tirunagaru, Gaia Bianco, Charlotte K. Y. Ng, Elisabetta Marangoni, Salvatore Piscuoglio, François-Clément Bidard, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P215.
https://doi.org/10.1158/1535-7163.TARG-21-P215
Published: 01 December 2021
View articletitled, Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer
Journal Articles

Abstract P210: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan

Free
Vijaya G. Tirunagaru, Mrinal M. Gounder, Prasanna R. Kumar, David S. Hong, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P210.
https://doi.org/10.1158/1535-7163.TARG-21-P210
Published: 01 December 2021
View articletitled, Abstract P210: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
Journal Articles

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

Free
Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, Stacey M. Bagby, Danielle Murphy, Jason Christiansen, Jennifer D. Hintzsche, Anh Le, Todd M. Pitts, Keith Wells, Allison Applegate, Carol Amato, Pratik Multani, Edna Chow-Maneval, John J. Tentler, Yiqun G. Shellman, Matthew J. Rioth, Aik-Choon Tan, Rene Gonzalez, Theresa Medina, Robert C. Doebele, William A. Robinson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 222–231.
https://doi.org/10.1158/1535-7163.MCT-17-0472
Published: 01 January 2018
View articletitled, ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Open the PDF for ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms in another window
Includes: Supplementary data
Journal Articles

Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions

Free
Adriana Estrada-Bernal, Andrea E. Doak, Anh T. Le, Hengbo Zhu, Nan Chen, Shevan Silva, Jeff B. Smaill, Adam V. Patterson, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A157.
https://doi.org/10.1158/1535-7163.TARG-17-A157
Published: 01 January 2018
View articletitled, Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions
Journal Articles

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Free
Sarah K. Nelson-Taylor, Anh T. Le, Minjae Yoo, Laura Schubert, Katie M. Mishall, Andrea Doak, Marileila Varella-Garcia, Aik-Choon Tan, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (8): 1623–1633.
https://doi.org/10.1158/1535-7163.MCT-17-0008
Published: 02 August 2017
View articletitled, Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
Open the PDF for Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Free
David S. Hong, Marcia S. Brose, Robert C. Doebele, Alice T. Shaw, Afshin Dowlati, Todd M. Bauer, Anna F. Farago, Adriana Estrada-Bernal, Anh T. Lee, Michael C. Cox, Nisha Nanda, Jennifer A. Low, Howard A. Burris, III
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR13.
https://doi.org/10.1158/1535-7163.TARG-15-PR13
Published: 01 December 2015
View articletitled, Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Journal Articles

Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor

Free
Adriana Estrada-Bernal, Anh T. Le, Brian Tuch, Tatiana Kutateladze, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C65.
https://doi.org/10.1158/1535-7163.TARG-15-C65
Published: 01 December 2015
View articletitled, Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor